GlycoMimetics postpones $60 million IPO – NASDAQ
|
GlycoMimetics postpones $ 60 million IPO
NASDAQ GlycoMimetics, a clinical-stage biotech developing treatments for sickle cell episodes and AML, postponed its IPO on Friday. The Gaithersburg, MD-based company was founded in 2003 and booked $ 12 million in sales for the 12 months ended June 30, 2013 … |
